JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT00578240Molecular Studies and Clinical Correlations in Human Prostatic DiseaseMemorial Sloan Kettering Cancer Center · Prostate CancerActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03903835ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerKarolinska Institutet · Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingJNJCollaboratorAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT04165564DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive BiomarkersBoston University · Pulmonary DiseaseActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05300451Daratumumab in HLA Desensitization Prior to TransplantationBarry A. Boilson · Cardiac TransplantEnrolling by invitationJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06062537Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma PatientsIntergroupe Francophone du Myelome · Multiple MyelomaActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06651489Efficacy of Guselkumab in Treating Hailey Hailey DiseaseYale University · Hailey Hailey DiseaseRecruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06149910Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple MyelomaAll4Cure · Multiple MyelomaRecruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- May 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05757869A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationJanssen Research & Development, LLC · Atrial FibrillationActive, not recruitingJNJLeadBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03451851A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic...Janssen Research & Development, LLC · PsoriasisActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Jul 19, 2023Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06866782European Registry of Next Generation Imaging in Advanced Prostate CancerFundacio Puigvert · Prostate CancerRecruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 23, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04644770A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT01982890Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over TimeUniversité de Sherbrooke · Telomere Length in Healthy ControlsEnrolling by invitationJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 28, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · LymphomaActive, not recruitingKPTIQCollaboratorJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT02908906A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal...Janssen Research & Development, LLC · NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 17, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03473743A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerJanssen Research & Development, LLC · Urothelial CarcinomaActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Sep 30, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03492177A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActelion · Pulmonary Arterial HypertensionActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Mar 28, 2022Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT03655223Early Check: Expanded Screening in NewbornsRTI International · Spinal Muscular AtrophyActive, not recruitingSRPTCollaboratorJNJCollaboratorILMNCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT03848052Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)UNICANCER · Lung Cancer
- Enrollment
- Locked
- Primary completion
- Oct 24, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT04662580ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerJanssen Research & Development, LLC · Metastatic Prostate CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05778097Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Prostate CancerNot yet recruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Aug 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06085586Fibulink Syndesmosis Repair System With Early Full-Weight BearingMaimonides Medical Center · Ankle FracturesRecruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06193863An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who...Bayer · Prevention of Venous ThromboembolismActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 30, 2026Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06217107Wellness & Workforce Solution for Lupus/Lupus NephritisMorehouse School of Medicine · Lupus NephritisRecruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 12 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.